Xcovery Holdings, Inc.
10
0
2
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
2 terminated/withdrawn out of 10 trials
66.7%
-19.8% vs industry average
10%
1 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Role: lead
Treating Patients With Melanoma and ALK Alterations With Ensartinib
Role: collaborator
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Role: collaborator
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Role: lead
BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Role: lead
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Role: collaborator
A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions
Role: lead
Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Role: lead
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
Role: collaborator
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Role: collaborator
All 10 trials loaded